# OnCo record varnimcabtagene-autoleucel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/varnimcabtagene-autoleucel/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "varnimcabtagene-autoleucel" ;
  schema:name "Varnimcabtagene autoleucel"@en ;
  schema:alternateName "var-cel"@en, "IMN-003A"@en, "ARI-0001"@en, "Qartemi" ;
  schema:description "India's second approved CAR-T therapy, a Bengaluru-made version of a Spanish hospital's academic CD19 cell therapy, for lymphoma that has come back after other treatments."@en ;
  schema:url <https://onco.cc/drugs/varnimcabtagene-autoleucel/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.immuneel.com>, <https://doi.org/10.1182/blood-2023-181585>, <https://doi.org/10.1002/hon.3165_632>, <https://doi.org/10.1111/bjh.19170> ;
  onco:status "approved" ;
  onco:modality "CAR-T (CD19, academic origin)" ;
  onco:approval "IN 2024: Relapsed or refractory B-cell lymphoma" ;
  onco:related <https://onco.cc/drugs/talicabtagene-autoleucel/>, <https://onco.cc/drugs/tisagenlecleucel/> ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/all-leukemia/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/point-of-care-cell-manufacturing/> ;
  onco:targets <https://onco.cc/targets/cd19/> ;
  onco:companies <https://onco.cc/companies/immuneel/> ;
  onco:institutions <https://onco.cc/institutions/narayana-health/> ;
  onco:terms <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/> ;
  onco:trials <https://onco.cc/trials/imagine-varnimcabtagene/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/>, <https://onco.cc/bottlenecks/b-global-access/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-martinez-cibrian-br-j-haematol/> .